Flexible and Pending Monographs
|
|
- Theresa Wade
- 6 years ago
- Views:
Transcription
1 Flexible and Pending Monographs USP Approaches to Accommodate Multiple Approved Products Doreen McDonald Senior National Account Manager U.S. Pharmacopeial Convention
2 Flexible Monographs: Background From USP Guideline for Submitting Requests for Revision to USP-NF V5 January 2011 Flexible Monographs At times, an ingredient and/or a drug product, including dietary supplement ingredients and products and biologicals and biotechnological ingredients and products, exhibit different attributes that have been determined by the FDA not to impact their safety and/or efficacy, i.e., their identity as official ingredients and products impurities, hydrates, and dissolution cases. In these instances, USP will allow different tests, procedures, and/or acceptance criteria reflecting these different attributes within a single monograph, with suitable validation, under its flexible monograph approach. 2
3 Flexible Monographs: Rationale Flexible to account for different routes of synthesis Control of impurities utilizes the approaches contained in ICH Q3A, Q3B, and Q3C Multiple dissolution procedures, especially for extended release products Considers hydrates/solvates, polymorphs Unambiguous document in support of ORA inspection May need procedure-specific USP Reference Standards 3
4 Flexible Monographs: Labeling General Notices : Applicability of Test Procedures multiple procedures may be included in particular monographs specifically for the purpose of assuring the availability of an appropriate procedure for a particular product. In such cases, a labeling statement to indicate the appropriate application of the procedure(s) will be included in the monograph. A labeling statement is not required if Test 1 is used. 4
5 Flexible Monographs: Labeling Always follow the Labeling requirement in the monograph label indicates which (test) is used label indicates which (test) is used if it does not meet Test 1 Not always same for APIs or Drug Products May be Labeling requirement called out as a monograph component May be requirement defined within a Test 5
6 Flexible Monographs: Examples Loratadine Drug Substance Meloxicam Drug Substance Paclitaxel Drug Substance Paroxetine Drug Substance Potassium Chloride Extended-Release Tablets Theophylline Extended-Release Capsules 6
7 Flexible Monographs: Specific Example #1 Loratadine drug substance Labeling If a test for Related compounds other than Test 1 is used, then the labeling states with which Related compounds test the article complies. Related compounds [note On the basis of the synthetic route, perform either Test 1 or Test 2. Test 2 is recommended if 4,8-dichloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin- 11-one is a potential related compound. ] TEST 1 TEST 2 7
8 Flexible Monographs: Specific Example # 1 (cont.) USP Reference standards <11> USP Loratadine RS USP Loratadine Related Compound A RS 8-Chloro-6,11-dihydro-11(4-piperidylidene)-5Hbenzo[5,6]cyclohepta[1,2-b] pyridine. C19H19ClN USP Loratadine Related Compound B RS 8-Chloro-6,11-dihydro-11(N-methyl-4-piperinylidene)-5Hbenzo[5,6]cyclohepta[1,2-b]pyridine. C20H21ClN USP Loratadine Related Compound A and B RS are called for only in TEST 2 8
9 Flexible Monographs: Specific Example #2 Meloxicam drug substance IMPURITIES Organic Impurities, Procedure 1, Perform either Procedure 1 or Procedure 2, depending on the manufacturing process used (Test details ) Organic Impurities, Procedure 2, If an article complies with this test, the labeling indicates that it meets the requirements under Organic Impurities, Procedure 2. (Test details ) 9
10 Flexible Monographs: Specific Example #3 Paroxetine Hydrochloride Labeling Label it to indicate whether it is the anhydrous or the hemihydrate form. Label it to indicate with which impurity tests the article complies. Chromatographic purity [note On the basis of the synthetic route, perform either Test 1 or Test 2. Test 2 is recommended if paroxetine related compound F or paroxetine related compound G is a potential related compound. ] 10
11 Flexible Monographs: Specific Example #4 Potassium Chloride Extended-Release Tablets Labeling The labeling states with which Assay preparation the product complies only if Assay preparation 1 is not used. Assay Assay preparation 1 Assay preparation 2 (For formulations containing crystals coated with hydrophobic polymers) 11
12 Flexible Monographs: Specific Example #5 Theophylline Extended-Release Capsules Labeling The labeling indicates whether the product is intended for dosing every 12 or 24 hours, and states with which in vitro Dissolution Test the product complies. FOR PRODUCTS LABELED FOR DOSING EVERY 12 HOURS TEST 1 If the product complies with this test, the labeling indicates that it meets USP Dissolution Test 1 TEST 2 TEST 5 TEST 9 TEST 3 TEST 7 TEST 10 TEST 4 TEST 8 12
13 Flexible Monographs: Specific Example #5 (cont.) Theophylline Extended-Release Capsules FOR PRODUCTS LABELED FOR DOSING EVERY 24 HOURS TEST 6 If the product complies with this test, the labeling indicates that it meets USP Dissolution Test 6. 13
14 Pending Monographs: Objectives Enables monograph development and publication before FDA approval has been granted to a generic manufacturer Ultimate purpose is to have an official USP-NF monograph ready as soon as possible after FDA approval of an application (i.e., ANDA, BLA) USP Pending Monographs web site is 14
15 Pending Monographs: Sponsor Requirements Available to sponsors who have filed or intend to file with FDA an Abbreviated New Drug Application (ANDA) or Abbreviated New Animal Drug Application (ANADA) within six months; or Who have filed or intend to file with FDA a Biosimilar or Interchangeable Biologics License Application (a Public Health Service Act 351(k) BLA) within six months; or Who have submitted a Drug Master File (DMF) for an article to FDA; or Whose substance is or will be the subject of a Time and Extent Application or citizen petition to amend an FDA OTC drug monograph. 15
16 Pending Standards: Requirements Documentation Statement of intent to file an ANDA, ANADA or BLA within six months Copy of the DMF filing letter Confidentiality Sponsor may request that all or part of Request for Revision be viewed only by USP and FDA for a specified time before the Draft Pending Monograph is posted 16
17 Pending Standards: Process Three main stages for Pending Monographs: Draft (on USP website; 90-day comment) Authorized (by USP Expert Committee) Official in USP/NF (by Revision Bulletin after sponsor receives FDA approval) 17
18 Pending Monographs: Process Sponsor submits monograph; development begins Draft Pending Monograph is posted for 90-day public review period Relevant Expert Committee(s) ballots Not approved Approved Authorized Pending Monograph is posted Determine next steps FDA approves Sponsor s ANDA, ANADA or BLA Relevant Expert Committee(s) ballots Not approved Approved Pending Monograph becomes official via Revision Bulletin (Official date is not less than 6 mos. after the posting) Official monograph published in USP-NF or Supplement 18
19 What if there is an existing official USP or NF monograph? If there is an existing official USP or NF monograph, then information from the Authorized Pending Monograph will be merged with the existing monograph, as appropriate, to create a monograph that reflects all FDA-approved articles (see the Guideline for Submitting Requests for Revision to USP NF). This revision to the existing monograph will advance to official status in the USP-NF via a Revision Bulletin and will be official six months after posting. 19
20 Commentary Minor changes to the original proposal are acceptable without another round of public review and comment; however, the EC needs to consider the impact of more substantial changes. Generally, acceptance criteria should not be tightened based on comments received without republication. Pending Monographs include Commentary information in the Briefing rather than in a separate document. 20
21 USP Reference Standards Unless USP determines otherwise, if the proposed monograph includes the use of a new USP Reference Standard then USP will not publish the proposed monograph on its Web site until it has received the necessary reference material bulk candidate(s) Any USP Reference Standard developed in support of a Pending Monograph may be available for sale at any time before or after Web site publication of the Draft or Authorized Pending monograph 21
22 Pending Monographs: Status 132 unique Pending monographs published to date 33 currently in Draft 77 currently Authorized 22 have migrated to Official status in USP-NF Approximately, 75% of Pending monographs are received and 36% are published by USP before receipt of a proposal from an NDA or ANDA holder. 22
23 Flexible and Pending Monograph: Summary Flexible and Pending monographs improve public health by Enhancing the traditional path of USP-NF revisions Broadening the applicability of USP-NF standards to be more inclusive Allowing earliest participation of ANDA/ANADA/BLA applicants in the development of new monographs 23
24
BRIEFING. . Over time, 466 may be used less frequently and may be withdrawn.
Page 1 of 13 BRIEFING 1086 USP 37 page 828. As part of an ongoing monograph modernization initiative, the United States Pharmacopeial Convention (USP) is updating this general chapter, 1086 Impurities
More informationCMC Considerations for 505(b)(2) Applications. Monica Cooper, Ph.D. FDA/CDER/OPS/ONDQA AAPS Annual Meeting Washington, D.C.
CMC Considerations for 505(b)(2) Applications Monica Cooper, Ph.D. FDA/CDER/OPS/ONDQA AAPS Annual Meeting Washington, D.C. October 2011 1 Introduction Outline Brief overview of FDA drug approval pathways
More informationCGMP Requirements for Investigational Products
PREP #6 CGMP Requirements for Investigational Products Ji-Eun Kim, RPh, PhD Research Pharmacist Regulatory Affairs Office of Research Compliance December 6, 2016 1 CME Disclosure Statement Northwell Health
More informationAnalytical Procedures and Methods Validation for Drugs and Biologics
Final Guidance for Industry Analytical Procedures and Methods Validation for Drugs and Biologics Analytical procedures and Method Validation June 21, 2016 Lokesh Bhattacharyya Chief, LACBRP/DBSQC OCBQ/CBER/FDA
More informationRole of USP Monographs and. General Chapters. Steve Zigler, Ph.D.
Role of USP Monographs and General Chapters Steve Zigler, Ph.D. Siemens PETNET Solutions USP Disclosure I have served as a USP volunteer in the area of PET drugs for 15 years Member of various Expert Committees
More informationAnalytical Procedures and Methods Validation for Drugs and Biologics
Analytical Procedures and Methods Validation for Drugs and Biologics Lucinda (Cindy) Buhse, Ph. D. Acting Director, Office of Testing and Research Office of Pharmaceutical Science CDER, FDA CHPA Quality
More informationQuality Issues for Clinical Trial Materials: The Chemistry, Manufacturing and Controls (CMC) Review
Quality Issues for Clinical Trial Materials: The Chemistry, Manufacturing and Controls (CMC) Review Presented by Erika E. Englund, Ph.D. Slides courtesy of Dorota Matecka, Ph.D. Office of Pharmaceutical
More informationInternational Pharmaceutical Excipients Council Of The Americas
October 6, 2008 Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm. 1061 Rockville, MD 20852 Subject: FDA Draft Guidance for Industry, Residual Solvents in Drug
More informationGuidance for Industry
Draft-t for Implementation Guidance for Industry ANDAs: Impurities in Drug Substances DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding
More informationHow we set specifications for impurities (including Genotoxic impurities) 24 May 2017 Elisabeth Kovacs, Apotex CSO Chemistry and Analytical Sci.
2017 AAM CMC Workshop How we set specifications for impurities (including Genotoxic impurities) 24 May 2017 Elisabeth Kovacs, Apotex CSO Chemistry and Analytical Sci. The information within this presentation
More informationCANADA (HEALTH CANADA)
1 GMP GAZETTE TM May 2016 HPFBI CANADA (HEALTH CANADA) No updates NNHPD NHPs Final Monograph for Antiseptic Skin Cleanser Who`s Affected? Companies seeking NPN or DIN for topical antiseptic hand cleansers
More informationGPhA Fall Technical Conference Nov 2-5, 2015 Bethesda, MD ICH M7 Guidance Overview and Current FDA Perspectives
GPhA Fall Technical Conference Nov 2-5, 2015 Bethesda, MD ICH M7 Guidance Overview and Current FDA Perspectives Stephen Miller, Ph.D. CMC-Lead; Office of New Drug Products Office of Pharmaceutical Quality
More informationHow to Avoid Common Deficiencies in INDs and NDAs. Ramesh Raghavachari, Ph.D. Branch Chief, Branch IX ONDQA/OPS/CDER
How to Avoid Common Deficiencies in INDs and NDAs Ramesh Raghavachari, Ph.D. Branch Chief, Branch IX ONDQA/OPS/CDER 1 Structure of FDA Office of Commissioner Chief Scientist FOODS Medical Products & Tobacco
More informationCOMMERCIAL PRODUCT STABILITY
COMMERCIAL PRODUCT STABILITY Being Responsible for your Tweener, Senior Citizen and Hospice Stage Products Melissa Lambert Global Head Stability in Quality & Compliance Management, R&D Director Quality
More information9/2/2014. USP Monograph Modernization. Todays topics. USP basic. Todays topics. - USP basic. - USP publications. - USP monograph modernization
USP Monograph Modernization Procedure Review and Development Donald Min 2 USP basic Since USP's founding in 1820, our operations have grown exponentially: from 11 volunteers collaborating from their respective
More informationQuestion-based Review (QbR)
Question-based Review (QbR) Rebecca L. Owen, Ph.D. Team Leader, Feed/Topical Team Division of Manufacturing Technologies ONADE/CVM/FDA Outline Background on CMC Filing Requirements What is QbR? QbR at
More informationGuidance for Industry
Guidance for Industry ANDAs: Blend Uniformity Analysis DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding this draft document should
More informationNew and Revised Draft Q&As on Biosimilar Development and the BPCI Act (Revision 2)
New and Revised Draft Q&As on Biosimilar Development and the BPCI Act (Revision 2) Guidance for Industry DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and
More informationInspections and ANDA Review: CDER/OC/OMQ s Role
Inspections and ANDA Review: CDER/OC/OMQ s Role Francis Godwin, Acting Director Office of Manufacturing Quality Office of Compliance Center for Drug Evaluation and Research GPhA 2016 Fall Technical Conference
More informationOffice of Pharmaceutical Quality Update on GDUFA
Office of Pharmaceutical Quality Update on GDUFA Lucinda (Cindy) Buhse, Ph.D. Director, Office of Testing and Research Office of Pharmaceutical Quality Center for Drug Evaluation and Research, FDA 2016
More informationSTIMULI TO THE REVISION PROCESS
Page 1 of 6 STIMULI TO THE REVISION PROCESS Stimuli articles do not necessarily reflect the policies of the USPC or the USP Council of Experts USP's Nomenclature Initiatives Angela G. Long, M.S.; Andrzej
More informationCATEGORY Advertising. CATEGORY Biopharmaceutics. CATEGORY Biosimilarity
CATEGORY Advertising Guidance Agenda: New & Guidances CDER is Planning to Publish During Calendar Year 2016 (See the Good Guidance Practices (GGPs) regulation on this Web page or 21 CFR 10.115 for details
More informationCATEGORY Advertising. CATEGORY Biopharmaceutics. CATEGORY Biosimilarity
Guidance Agenda: New & Revised Draft Guidances CDER is Planning to Publish During Calendar Year 2015 (See the Good Guidance Practices (GGPs) regulation on this Web page or 21 CFR 10.115 for details about
More informationExperience with Health Canada s Approach for Post-Approval Changes. Kiran Krishnan Vice President US Regulatory Affairs September 2014
Experience with Health Canada s Approach for Post-Approval Changes Kiran Krishnan Vice President US Regulatory Affairs September 2014 Important Quotes to consider Dr. Janet Woodcock on desired state: A
More informationGuidance for Industry
Guidance for Industry ANDAs: Impurities in Drug Products DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding this draft document should
More informationOverview of USP Activities and How to Get Involved
Overview of USP Activities and How to Get Involved Ravi Ravichandran, Ph.D. Principal Scientific Liaison, Chemical Medicines United States Pharmacopeia Outline Introduction to the USP USP Standard Setting
More informationReference Standard Characterization. Steve Lane. General Manager, NSF Reference Standards.
Reference Standard Characterization Steve Lane General Manager, NSF Reference Standards www.nsf-rs.org Regulatory Bodies will require that an Excipient: Be safe in the amount or dose used Meet applicable
More informationReplacing Analytical Methods for Release and Stability Testing A Regulatory Perspective
Replacing Analytical Methods for Release and Stability Testing A Regulatory Perspective Presentation at The IVT s 12 th Annual Analytical Procedure and Method Validation Conference Dec 12, 2016 Lokesh
More informationMINOCYCLINE HYDROCHLORIDE National Drug Code Directory
65862-209-01 MINOCYCLINE HYDROCHLORIDE National Drug Code Directory The Drug Listing Act of 1972 requires registered drug establishments to provide the Food and Drug Administration (FDA) with a current
More informationRegulatory expectations on impurities in drug substances - Pavia, October 2, Luisa Torchio Euticals SpA
Regulatory expectations on impurities in drug substances - Pavia, October 2, 2015 Luisa Torchio Euticals SpA An Impurity is defined as any substance or element present in a drug substance (DS) that is
More informationCopyright. Jeremiah J. Kelly (2015). All rights reserved. Further dissemination without express written consent strictly prohibited.
Statutory Framework for Biologics Drugs Investigational Use Application IND Pre-Market Approval Applications 505(b)(1) NDA 505(b)(2) NDA 505(j) ANDA Over-the-Counter (OTC) Non- Rx Drugs Monograph Biologics
More informationWhile the recognition
Designing the Perfect Change Control System Change control systems today are expected to be designed in a way that provides a system to not only document and approve changes, but also to anticipate change
More informationVariation Regulations (EU)
Variation Regulations (EU) Headlines of the Update APIC c view Hilde Vanneste APIC Task Force leader Hilde.Vanneste@its.jnj.com 1 Content Scope of regulation: Type of procedures and hence 2 strands Current
More informationMedicines Control Authority of Zimbabwe
EFV... QUALITY INFORMATION SUMMARY (QIS) FOREWORD The Quality Information Summary (QIS) template should be completed to provide a condensed summary of the key quality information for product dossiers (PDs)
More informationEstablished Conditions: Reportable CMC Changes for Approved Drug and Biologic Products Guidance for Industry
Established Conditions: Reportable CMC Changes for Approved Drug and Biologic Products Guidance for Industry DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments
More informationPRAZOSIN National Drug Code Directory
59762-5310-1 PRAZOSIN The Drug Listing Act of 1972 requires registered drug establishments to provide the Food and Drug Administration (FDA) with a current list of all drugs manufactured, prepared, propagated,
More informationGuidance for Industry
Guidance for Industry Handling and Retention of BA and BE Testing Samples U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) May 2004
More informationThe Deemed to be a License Provision of the BPCI Act Questions and Answers Guidance for Industry
The Deemed to be a License Provision of the BPCI Act Questions and Answers Guidance for Industry DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions
More informationFood and Drug Administration (FDA) 101
Food and Drug Administration (FDA) 101 What is the Food and Drug Administration (FDA)? The FDA is an agency within the U.S. Department of Health and Human Services that is responsible for protecting the
More informationA GUIDELINE ON DOSSIER REQUIREMENTS FOR TYPE I VARIATIONS November 1999
EUROPEAN COMMISSION ENTERPRISE DIRECTORATE-GENERAL Pharmaceuticals and cosmetics Final Revision 0 NOTICE TO APPLICANTS A GUIDELINE ON DOSSIER REQUIREMENTS FOR TYPE I VARIATIONS November 1999 This guideline
More informationLEADER IBUPROFEN COLD AND SINUS National Drug Code Directory
37205-199-60 LEADER IBUPROFEN COLD AND SINUS National Drug Code Directory The Drug Listing Act of 1972 requires registered drug establishments to provide the Food and Drug Administration (FDA) with a current
More informationRegulatory Expectations for Method Transfers: Health Canada's Perspective CMC Strategy Forum Methods on the move January 23, 2017
Regulatory Expectations for Method Transfers: Health Canada's Perspective CMC Strategy Forum Methods on the move January 23, 2017 Hugo Hamel, Senior Biologist/Evaluator, BGTD Overview of the Post-NOC Changes
More informationVALPROIC ACID National Drug Code Directory
63739-251-10 VALPROIC ACID National Drug Code Directory The Drug Listing Act of 1972 requires registered drug establishments to provide the Food and Drug Administration (FDA) with a current list of all
More informationGDUFA II Pre-ANDA Program Meetings for Complex Products
GDUFA II Pre-ANDA Program Meetings for Complex Products Robert Lionberger Director, Office of Research and Standards Office of Generic Drugs AAM Fall Technical Meeting November 7, 2017 GDUFA II Pre-ANDA
More informationPHARMACEUTICAL SCIENCES - QUESTIONS AND ANSWERS
PHARMACEUTICAL SCIENCES - QUESTIONS AND ANSWERS The document PHARMACEUTICAL SCIENCES - QUESTIONS AND ANSWERS is intended to provide clarification on a number of issues that relate to Quality (e.g., Chemistry
More informationAdopted by CHMP for release for consultation 15 December Start of public consultation 15 December 2016
1 September 2017 EMA/CHMP/ICH/809509/2016 Committee for Human Medicinal Products ICH guideline Q11 on development and manufacture of drug substances (chemical entities and biotechnological / biological
More informationStatus of Food and Drug Administration Programs and Activities During the Current Government Shutdown
Status of Food and Drug Administration Programs and Activities During the Current Government Shutdown Agency-Wide FDA can perform activities necessary to address imminent threats to the safety of human
More informationReplacing Analytical Methods for Release and Stability Testing CBER Perspective
Replacing Analytical Methods for Release and Stability Testing CBER Perspective Presentation at the CMC Strategy Forum January 27, 2014 Lokesh Bhattacharyya Chief, Lab of Analytical Chemistry and Blood
More informationState of Office of Pharmaceutical Quality (OPQ) Address
State of Office of Pharmaceutical Quality (OPQ) Address Giuseppe Randazzo, M.S. Director, Office of Program and Regulatory Operations Office of Pharmaceutical Quality Center for Drug Evaluation and Research,
More informationAnalytical Methods Development and Validation
Understanding and Implementing Efficient Analytical Methods Development and Validation Jay Breaux, Kevin Jones, and Pierre Boulas Analytical methods development and validation play important roles in the
More informationLatest USP Initiatives: Monographs, General Chapters, and Compounding
Latest USP Initiatives: Monographs, General Chapters, and Compounding Jim Ponto, MS, RPh, BCNP Disclosures Volunteer member on several USP Expert Committees and Expert Panels associated with radiopharmaceutical
More informationCANADA (HEALTH CANADA)
LEADERS 1 THE GMP GAZETTE TM February 2015 HPFBI CANADA (HEALTH CANADA) Blood Establishment Registration Application: Form and Instructions - (FRM-0353) Who s affected? Anyone who plans to perform the
More informationADVIL CONGESTION RELIEF National Drug Code Directory
0573-0195-41 ADVIL CONGESTION RELIEF National Drug Code Directory The Drug Listing Act of 1972 requires registered drug establishments to provide the Food and Drug Administration (FDA) with a current list
More informationBiotechnology Industry Organization 1225 Eye Street NW, Suite 400 Washington, DC 20006
Biotechnology Industry Organization 1225 Eye Street NW, Suite 400 Washington, DC 20006 December 4, 2003 Dockets Management Branch (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm. 1061 Rockville,
More informationStrategies for IND Filing Success: Chemistry, Manufacturing and Controls
Strategies for IND Filing Success: Chemistry, Manufacturing and Controls October 21, 2016 Presented by: Sharon Ayd, Ph.D., MBA Chief Scientific Officer and SVP, Pharmaceuticals document contains proprietary
More informationCurrent version 13 October 2016
Implementation Working Group ICH Q11 Guideline: DEVELOPMENT AND MANUFACTURE OF DRUG SUBSTANCES (CHEMICAL ENTITIES AND BIOTECHNOLOGICAL/BIOLOGICAL ENTITIES) and Current version 13 October 2016 In order
More informationInspections, Compliance, Enforcement, and Criminal Investigations
Inspections, Compliance, Enforcement, and Criminal Investigations Nostrum Laboratories Inc 4/27/09 Department of Health and Human Services Public Health Service Food and Drug Administration Kansas City
More information2nd FDA/PQRI Conference on Advancing Product Quality
2nd FDA/PQRI Conference on Advancing Product Quality Generic Pharma Perspective on the Identification of Critical Quality Attributes and Critical Process Parameters Bruce D. Johnson, Ph.D. Vice President
More informationConnection Between Quality, Safety, and Efficacy
PQRI-FDA Workshop on Process Drift Bethesda, Maryland Connection Between Quality, Safety, and Efficacy Roger L. Williams, M.D. United States Pharmacopeial Convention December 1 3, 2010 Topics Overview
More informationBACTINE ORIGINAL FIRST AID National Drug Code Directory
0280-0700-04 BACTINE ORIGINAL FIRST AID The Drug Listing Act of 1972 requires registered drug establishments to provide the Food and Drug Administration (FDA) with a current list of all drugs manufactured,
More informationPharmaceutical Reference Standards: Overview and Role in Global Harmonization
Matthew Borer, Ph.D., Advisor Pharmaceutical Reference Standards: Overview and Role in Global Harmonization 3rd DIA China Annual Meeting Beijing, China, 16-18 May, 2011 What is a Pharmaceutical Reference
More informationCopyright. Jeremiah J. Kelly (2015). All rights reserved. Further dissemination without express written consent strictly prohibited.
Copyright. Jeremiah J. Kelly (2015). All rights reserved. Further dissemination without express written consent strictly prohibited. Special Review Designations & Approval Pathways Special Designations
More informationPhase Appropriate GMPs for IMPs. Presented by: Karen S. Ginsbury For: IFF, October 31, Nov 02, 2017
Phase Appropriate GMPs for IMPs Presented by: Karen S. Ginsbury For: IFF, October 31, Nov 02, 2017 1 Lets start with References https://mhrainspectorate.blog.gov.uk/2016/0 5/20/manufacture-of-investigationalmedicinal-products-frequently-askedquestions/
More informationApplication of Quality by Design (QbD) in product development. James E. Polli September 16, 2015
Application of Quality by Design (QbD) in product development James E. Polli jpolli@rx.umaryland.edu September 16, 2015 Pharmaceutical Equivalence Same active ingredient(s) Same dosage form Same route
More information4 Key Considerations When Engaging A New GMP Contract Service Provider
Page 1 of 6 Guest Column April 12, 2017 4 Key Considerations When Engaging A New GMP Contract Service Provider By Bikash Chatterjee, President and Chief Science Officer, Pharmatech Associates Integrating
More informationProposed Revision of USP General Chapter Radiopharmaceuticals for Positron Emission Tomography Compounding <823>
Proposed Revision of USP General Chapter Radiopharmaceuticals for Positron Emission Tomography Compounding Ravi Ravichandran, Ph.D. Steve Zigler, Ph.D. February 21, 2011 Agenda Rationale for the
More informationA Generic Industry Perspective on Establishing Impurity Limits And a Corresponding Control Strategy
A Generic Industry Perspective on Establishing Impurity Limits And a Corresponding Control Strategy Nicholas Cappuccino, PhD Vice-President, Head of Quality and Scientific Affairs Dr. Reddy s Laboratories,
More informationPHARMA KNOWLEDGE PARK
GUIDELINES 2013 WWW.NOORMD.COM A COMPILATION BY ON PHARMACEUTICAL REGULATORY GUIDELINES INTRODUCED / REVISED DURING THE YEAR 2013. Page 2 ICH Assessment and control of DNA reactive (mutagenic) impurities
More informationQuality of raw materials and manufacturing of advanced therapies. Fouad Atouf, Ph.D. Head, Global Biologics July 12, 2018
Quality of raw materials and manufacturing of advanced therapies Fouad Atouf, Ph.D. Head, Global Biologics July 12, 2018 Evolution of the compendia 1820: a single recipe book 2018: Procedures and acceptance
More informationPharmaceutical Compounding Sterile and Nonsterile Preparations. Jeanne Sun, PharmD
Pharmaceutical Compounding Sterile and Nonsterile Preparations Jeanne Sun, PharmD Agenda Legal Framework Overview Pharmaceutical Compounding Nonsterile Preparations Pharmaceutical Compounding
More informationQ & A on USP General Chapter <823> Revision Proposal Webinar held on 21 February 2011
1. For day of use calibration, why does the chapter recommend only 2 injections of the known standard versus current standard of 3? Response: The current Chapter does not specify a number of standard
More informationValidation/Verification of Test Methods An FDA Perspective. Laure H. Kairawicz, Ph.D. Senior Scientist Expert Witness
Validation/Verification of Test Methods An FDA Perspective Laure H. Kairawicz, Ph.D. Senior Scientist Expert Witness FD & C Act Overview Definition of drugs What cgmps are Finished Pharmaceuticals cgmp
More informationImpurities from degradation of Drug Substances
Impurities from degradation of Drug Substances REFERENCE 1. ICH - IMPURITIES IN NEW DRUG SUBSTANCES - Q3A(R2) 2. ICH - IMPURITIES IN NEW DRUG PRODUCTS - Q3B(R2) 3. ICH - VALIDATION OF ANALYTICAL PROCEDURES:
More informationStarting Material Selection for Type II Drug Master Files
Starting Material Selection for Type II Drug Master Files Ronald S. Michalak Quality Assessment Lead (Acting), Division of Lifecycle API Office of New Drug Products, OPQ/CDER/ FDA CDER Reorganization Office
More informationFormulation Development
Quality by Design and Formulation Development WF Busch Senior Application Development Specialist Dow Chemical Company IPEC Americas, Quality by Design Committee 5 May 2010 Disclaimer The views and opinions
More informationBUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE National Drug Code Directory
0409-9046-01 BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE National Drug Code Directory The Drug Listing Act of 1972 requires registered drug establishments to provide the Food and Drug Administration (FDA)
More informationInterim Policy on Compounding Using Bulk Drug Substances Under Section 503B of the Federal Food, Drug, and Cosmetic Act
Interim Policy on Compounding Using Bulk Drug Substances Under Section 503B of the Federal Food, Drug, and Cosmetic Act Guidance for Industry U.S. Department of Health and Human Services Food and Drug
More informationMedicine Variations Guideline
Medicine Variations Guideline National Health Regulatory Authority (NHRA) Kingdom of Bahrain 30 th March 2017 Version 2.0 Chief of Pharmaceutical Product Regulation: Dr/Roaya Al Abbasi Date: NHRA CEO Approval:
More informationConducted Under an IND to Support a
Using Foreign Clinical Trial Data not Conducted Under an IND to Support a US Application PDA Midwest Chapter Meeting March 15, 2018 2013 2017 Regulatory Compliance Associates Inc. All Rights Reserved.
More informationRegulations of Biologics in Taiwan
Regulations of Biologics in Taiwan Churn-Shiouh Gau, Ph.D. Executive Director, Taiwan 2013/2/13 1 Outlines Regulation of Drugs in Taiwan - Organizations Regulations for Marketing Approval for Drugs including
More informationCELECOXIB National Drug Code Directory
59762-1517-1 CELECOXIB National Drug Code Directory The Drug Listing Act of 1972 requires registered drug establishments to provide the Food and Drug Administration (FDA) with a current list of all drugs
More informationCYCLOPHOSPHAMIDE National Drug Code Directory
0781-3233-94 CYCLOPHOSPHAMIDE National Drug Code Directory The Drug Listing Act of 1972 requires registered drug establishments to provide the Food and Drug Administration (FDA) with a current list of
More informationGlossary of Abbreviations
Glossary of Abbreviations ANDA APhA Abbreviated New Drug Application American Pharmaceutical Association API Active Pharmaceutical Ingredient BA/BE Bioavailability/Bioequivalence BE Bioequivalence Bio
More informationGuidance for Industry ANDAs: Stability Testing of Drug Substances and Products
Guidance for Industry ANDAs: Stability Testing of Drug Substances and Products DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding this
More informationFAMILY CARE MUSCLE RUB PAIN RELIEVER National Drug Code Directory
65923-498-35 FAMILY CARE MUSCLE RUB PAIN RELIEVER National Drug Code Directory The Drug Listing Act of 1972 requires registered drug establishments to provide the Food and Drug Administration (FDA) with
More informationEU and FDA GMP Regulations: Overview and Comparison
THE QUALITY ASSURANCE JOURNAL, VOL. 2, 55 60 (1997) EU and FDA GMP Regulations: Overview and Comparison The increasing emphasis on global supply of drug products, as well as starting materials and investigational
More informationAn Overview of IQ s Position Paper: Early Development GMPs for Small-Molecule Specifications
An Overview of IQ s Position Paper: Early Development GMPs for Small-Molecule Specifications On behalf of Specifications Team Kirby Wong-Moon, Ph.D. Amgen Inc. Best Practices and Application of GMPs for
More informationCYCLOPHOSPHAMIDE National Drug Code Directory
10019-956-01 CYCLOPHOSPHAMIDE National Drug Code Directory The Drug Listing Act of 1972 requires registered drug establishments to provide the Food and Drug Administration (FDA) with a current list of
More informationCREON National Drug Code Directory
0032-3016-13 CREON The Drug Listing Act of 1972 requires registered drug establishments to provide the Food and Drug Administration (FDA) with a current list of all drugs manufactured, prepared, propagated,
More informationAPI Selection of Starting Materials Impact on First Cycle Approval
API Selection of Starting Materials Impact on First Cycle Approval Presented by Aloka Srinivasan, Ph.D. Vice President, Regulatory Affairs May 24, 2017 Trends in Selection of Regulatory Starting Materials
More informationBiosimilars: Questions and Answers Regarding Implementation of the Biologics Price Competition and Innovation Act of 2009
Biosimilars: Questions and Answers Regarding Implementation of the Biologics Price Competition and Innovation Act of 2009 Guidance for Industry U.S. Department of Health and Human Services Food and Drug
More informationMAGNEVIST National Drug Code Directory
50419-188-81 MAGNEVIST National Drug Code Directory The Drug Listing Act of 1972 requires registered drug establishments to provide the Food and Drug Administration (FDA) with a current list of all drugs
More informationVALPROIC ACID National Drug Code Directory
0121-4675-05 VALPROIC ACID National Drug Code Directory The Drug Listing Act of 1972 requires registered drug establishments to provide the Food and Drug Administration (FDA) with a current list of all
More information2017 AAM CMC Workshop
2017 AAM CMC Workshop SETTING PROPER IMPURITIES LIMITS - INCLUDING GENOTOXIC IMPURITIES INDUSTRY PERSPECTIVE Janet Vaughn, Sr. Director Regulatory Affairs Teva Pharmaceuticals USA 23 May, 2017 Disclaimer
More informationNew Drug Product Impurities
Title Page Image - with courtesy of the FDA CDER original web site at www. cder.fda.gov/ New Drug Product Impurities IAGIM Scientific Committee Block JD; Holmann E ; West P NEW DRAFT GUIDANCE FDA Viewpoint
More informationGUIDANCE ON VARIATIONS TO A PREQUALIFIED DOSSIER
RESTRICTED GUIDANCE ON VARIATIONS TO A PREQUALIFIED DOSSIER Since being presented to the Fortieth meeting of the WHO Expert Committee on Specifications for Pharmaceutical Preparations in October 2005 this
More informationGMP The Other Side of Chemistry, Manufacturing & Controls (CMC)
Overview of USFDA Drug Regulatory Requirements Pharmaceutical Quality and Facility Inspections (GMP) Session II 19 February 2014 Casablanca, Morocco GMP The Other Side of Chemistry, Manufacturing & Controls
More informationAn FDA Perspective on Atypical Active Ingredients
An FDA Perspective on Atypical Active Ingredients Presented by Steven Wolfgang, Ph.D. Center for Drug Evaluation and Research Office of Compliance Office of Drug Security, Integrity and Response steven.wolfgang@fda.hhs.gov
More informationChin Koerner Executive Director US Regulatory and Development Policy
Chin Koerner Executive Director US Regulatory and Development Policy Novartis Pharmaceuticals Corporation 1700 Rockville Pike Suite 510 Rockville, MD 20852 Tel 301.468.5607 Fax 301.468.5614 Email: Chin.Koerner@novartis.com
More informationOn the Q&A to the Guideline for Common Technical Documents
To: Public Health Bureau Prefectural Government Letter from PFSB/ELD 22 nd October 2001 From: Evaluation & Licensing Division, Pharmaceutical & Food Safety Bureau, The Ministry of Health, Labour and Welfare
More information